GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Price-to-Free-Cash-Flow

Qiagen NV (Qiagen NV) Price-to-Free-Cash-Flow : 30.93 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV Price-to-Free-Cash-Flow?

As of today (2024-04-26), Qiagen NV's share price is $41.08. Qiagen NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.33. Hence, Qiagen NV's Price-to-Free-Cash-Flow Ratio for today is 30.93.

The historical rank and industry rank for Qiagen NV's Price-to-Free-Cash-Flow or its related term are showing as below:

QGEN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.04   Med: 34.23   Max: 1106.53
Current: 30.93

During the past 13 years, Qiagen NV's highest Price-to-Free-Cash-Flow Ratio was 1106.53. The lowest was 15.04. And the median was 34.23.

QGEN's Price-to-Free-Cash-Flow is ranked worse than
55.56% of 90 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.885 vs QGEN: 30.93

Qiagen NV's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.44. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $1.33.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Qiagen NV was -47.70% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 25.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 8.20% per year.

During the past 13 years, Qiagen NV's highest 3-Year average Free Cash Flow per Share Growth Rate was 115.30% per year. The lowest was -38.00% per year. And the median was 3.10% per year.


Qiagen NV Price-to-Free-Cash-Flow Historical Data

The historical data trend for Qiagen NV's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Price-to-Free-Cash-Flow Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137.19 80.60 29.83 20.28 33.77

Qiagen NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.28 24.53 27.52 33.86 33.77

Competitive Comparison of Qiagen NV's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Qiagen NV's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Price-to-Free-Cash-Flow falls into.



Qiagen NV Price-to-Free-Cash-Flow Calculation

Qiagen NV's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=41.08/1.328
=30.93

Qiagen NV's Share Price of today is $41.08.
Qiagen NV's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.33.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Qiagen NV  (NYSE:QGEN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Qiagen NV Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board